Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
Haemophilia · 2025-09 · 31 (5) · 1092-1102
DOI: 10.1111/hae.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 17.07.2025. Verfasst von Daniel Kraemmer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Factor VIII, Hemophilia A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown.
Objectives
To estimate FVIIIeq of emicizumab using global assays of haemostasis. Patients/Methods We sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one‐stage assay (OSA). Using principal components (PC) or individual parameters as dependent and independent variables in linear regression with (1) FVIII and (2) emicizumab levels, respectively, we estimated FVIIIeq (95% CI) of emicizumab.
Results
We collected 253 samples from 110 PWHA and 41 samples from nine individuals on emicizumab prophylaxis. TGA parameters of emicizumab‐treated subjects clustered distinctly, with no correlation amongst samples with only endo‐/exogenous FVIII. Consequently, FVIIIeq varied substantially between parameters: Using individual TGA parameters, endogenous thrombin potential (ETP) and thrombin peak resulted in conversion factors of 0.85 (0.60–1.24) and 0.25 (0.15–0.37) IU/dL FVIIIeq per µg/mL emicizumab, respectively. CLA parameters showed broader overlap, with an FVIIIeq estimate of 0.82 (0.44–1.38).
Conclusion
Distinct clustering of emicizumab and FVIII samples in TGA leads to conflicting FVIIIeq estimates between parameters, highlighting systematic limitations and questioning their clinical usefulness. A, possibly conservative, FVIIIeq conversion factor estimate as determined by the thrombin peak could range from 0.15 to 0.37.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Institute of Clinical Biometrics, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Daniel Kraemmer, Cihan Ay, Ingrid Pabinger
Zitieren
APA
Kraemmer, D., Ay, C., Rejtő, J., Heinze, G., Quehenberger, P., Pabinger, I., & Königsbrügge, O. (2025). Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis. Haemophilia, 31(5), 1092-1102. https://doi.org/10.1111/hae.70085
Vancouver
Kraemmer D, Ay C, Rejtő J, Heinze G, Quehenberger P, Pabinger I, et al. Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis. Haemophilia. 2025;31(5):1092-1102. doi:10.1111/hae.70085
BibTeX
@article{Kraemmer2025,
author = {Kraemmer, Daniel and Ay, Cihan and Rejtő, Judit and Heinze, Georg and Quehenberger, Peter and Pabinger, Ingrid and Königsbrügge, Oliver},
title = {Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis},
journal = {Haemophilia},
year = {2025},
volume = {31},
number = {5},
pages = {1092--1102},
doi = {10.1111/hae.70085}
}
EUVIMED